Trying to break from the decade-old practice of using BTK inhibitors indefinitely to treat blood cancer, AstraZeneca has ...

Calquence plus Venclexta, with or without Gazyva, improved progression-free survival over the standard-of-care ...

Calquence starts working as soon as you start taking it. But it can take time to see results on laboratory or imaging tests. You’ll likely continue taking Calquence for as long as it’s ...

Positive results from the AMPLIFY Phase III trial have shown that adding AstraZeneca’s Calquence (acalabrutinib) to ...

Verition Fund Management LLC lowered its stake in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 66.0% in the third ...

Positive” results from the AMPLIFY Phase III trial showed AstraZeneca’s (AZN) Calquence in combination with venetoclax demonstrated a ...

Data from Eli Lilly and AstraZeneca could help doctors decide treatment order in chronic lymphocytic leukemia. Elsewhere, ...

Data from the Phase I/II TRANSCEND CLL 004 study evaluating the combination of Bristol Myers Squibb’s (BMS’s) Breyanzi ...

In a meta-analysis, second-generation BTK inhibitors were linked to a significantly low incidence of atrial fibrillation, ...

Developments in chronic lymphocytic leukemia (CLL) this year included the first CAR T-cell therapy approval for the chronic ...